HIKALPharmaceuticals
Hikal Ltd — PE Ratio & Valuation Analysis
₹147.08
-6.80%
Current P/E276.82xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E44.8x517.6% above avg
⚠️
771.3% Premium to Industry
HIKAL P/E 276.82x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹7.36 | ₹227 | 30.8x |
| 2024 | ₹5.64 | ₹391 | 69.2x |
| 2023 | ₹6.36 | ₹304 | 47.8x |
| 2022 | ₹13.02 | ₹410 | 31.5x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Hikal Ltd Valuation
Hikal Ltd (HIKAL) currently trades at 276.82x earnings. The Pharmaceuticals sector average PE is 31.77x. HIKAL commands a premium, reflecting high growth expectations. Historically, HIKAL has traded at an average PE of 44.8x — it is currently above that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
7.38%
Dividend Yield
0.62%
More on Hikal Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.